- Home
- GSAT vs AKRO Comparison
GSAT vs AKRO Comparison
Compare GSAT & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSAT | AKRO |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 4.5B |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GSAT | AKRO |
|---|---|---|
| Price | $69.10 | $54.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | $52.75 | ★ $73.56 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $262,202,000.00 | N/A |
| Revenue This Year | $10.89 | N/A |
| Revenue Next Year | $10.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.54 | N/A |
| 52 Week Low | $17.24 | $21.34 |
| 52 Week High | $70.83 | $58.40 |
Technical Indicators
Market Signals| Indicator | GSAT | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 66.54 |
| Support Level | $58.02 | $54.22 |
| Resistance Level | $62.68 | $54.70 |
| Average True Range (ATR) | 3.73 | 0.14 |
| MACD | 0.30 | -0.11 |
| Stochastic Oscillator | 85.91 | 64.18 |
Price Performance
Historical ComparisonAbout GSAT Globalstar Inc.
Globalstar Inc is a telecommunications company that derives revenue from the provision of mobile satellite services. Mobile satellite services are typically used by customers where existing terrestrial wireline and wireless communications networks are impaired or do not exist. The company provides communications services such as two-way voice and data transmission. In addition, one-way data transmission is also offered. Both services are offered using mobile or fixed devices. The company is an owner of satellite assets. It has one reportable segment: MSS business. The company generates the vast majority of its revenue within the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.